Blog

The institution of an ongoing IP education curriculum as part of the regular working rhythm of your company is key to protecting your most valuable IP assets.

The establishment of an Innovation Committee is a crucial first step in protecting existing IP assets, and creating a culture of IP awareness across your company.

A vital first step in ensuring your enterprise is positioned for ongoing growth and innovation is to assess the current state of IP alignment throughout your organization.

To ensure a strong market position, innovative companies go through three stages of growth to align their IP strategy with their overall business plan.

An effective IP strategy involves capturing innovation, greater oversight of the process, and protecting all IP assets. Successfully managing contracts and monitoring your competition are also necessary components.

Examine the three essential components of IP alignment and how they interconnect within a technology enterprise: IP awareness, IP protection, and IP counseling.

Improve market share and enterprise value by developing an understanding of IP alignment as a strategic priority.

Dilworth IP is excited to announce that we have formed a strategic affiliation with fellow intellectual property firm, Dilworth & Barrese.  With this new affiliation both firms will offer their respective current and future clients a broader array of technical and legal expertise. 

Dr. Anthony Sabatelli, Partner and Chair of Dilworth IP’s Biotech and Pharmaceutical IP practice group, has been appointed to serve on CURE’s Board of Directors. CURE (Connecticut United for Research Excellence) serves as the bioscience cluster for the state, and is a diverse community of small and large life and healthcare sciences companies, ranging in scope from therapeutics, to healthcare technology, to medical devices. Universities, government agencies, scientists, educators, mentors, students, entrepreneurs, business experts, service providers and investors further form the breadth of the network. Regarding his appointment, Dr. Sabatelli said that “I am honored to serve CURE in this capacity because it is an important advocate for the state’s bioscience community.”

Dr. Anthony Sabatelli and Dr. Jonathan Schuchardt, both Partners at Dilworth IP, will be presenting at the 250th American Chemical Society National Meeting and Exposition in Boston this Thursday, August 20th. The theme of this year’s meeting is Innovation: from Discovery to Application and both presentations will be part of the ACS’s Chemistry and the Law (CHAL) Division’s slate of talks.